Canada Markets open in 2 hrs 46 mins

Helix BioPharma Corp. (HBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.8500-0.0500 (-5.56%)
At close: 12:01PM EDT
Full screen
Previous Close0.9000
Open0.8600
Bid0.8500 x 0
Ask0.9100 x 0
Day's Range0.8300 - 0.8600
52 Week Range0.2500 - 1.6000
Volume26,220
Avg. Volume46,867
Market Cap119.963M
Beta (5Y Monthly)-0.17
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateMar. 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.10
  • Helix BioPharma Corp. Extends Period to Exercise Warrants
    ACCESSWIRE

    Helix BioPharma Corp. Extends Period to Exercise Warrants

    RICHMOND HILL, ON / ACCESSWIRE / April 9, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to extend the exercise period of a total of 2,837,000 outstanding common share purchase warrants (the "Warrants"), all of which are held by arm's length parties.

  • Helix BioPharma Corp. Announces Fiscal Second Quarter 2021 Results
    ACCESSWIRE

    Helix BioPharma Corp. Announces Fiscal Second Quarter 2021 Results

    RICHMOND HILL, ON / ACCESSWIRE / March 16, 2021 / Helix BioPharma Corp. (TSX:"HBP"), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal second quarter ended January 31, 2021.

  • Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw To Scientific Advisory Board
    ACCESSWIRE

    Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw To Scientific Advisory Board

    RICHMOND HILL, ON / ACCESSWIRE / February 16, 2021 / Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced the appointment of Dr.